ABOS
Acumen Pharmaceuticals, Inc.·Healthcare
2.47
1.594%(−0.04)
Market ClosedLast Updated: — ET
52W L: $0.8552W H: $3.60
ABOS NEWS
zacks.com
Mar 31
Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Acumen Pharmaceuticals (ABOS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
zacks.com
Mar 30
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and ADC Therapeutics SA (ADCT) have performed compared to their sector so far this year.
defenseworld.net
Mar 30
Analysts Set Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Target Price at $7.00
Shares of Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the four analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average
seekingalpha.com
Mar 26
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript
globenewswire.com
Mar 26
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the full year ended December 31, 2025 and provided a business update.
globenewswire.com
Mar 19
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
NEWTON, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2025 financial results on Thursday, March 26, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
